Low rate of follow-up colonoscopy after positive results of colorectal cancer screening in a Chinese urban core district

Authors:

Yawen Guo¹, Qingwu Jiang², Tetsuya Tanimoto³, Masahiro Kami⁴, Peng Peng⁵, Yongpin He¹, Xiaoming Yang¹, Xin Zhang¹, Wenjun Gao¹, Yanming Wang¹, Xiaoting Chu¹, Yunhui Wang¹, Shigeaki Kato^{6,7§}, Xiaocao Ding^{8, §}

Affiliations:

- 1 Department of Health Promotion, Shanghai Jingan Center for Disease Control and Prevention, Shanghai, China
- 2 Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China
- 3 Department of Internal Medicine, Jyoban Hospital of Tokiwakai Group, Jyoban Hospital, Iwaki, Fukushima, Japan
- 4 Medical Governance Research Institute, Tokyo, Japan
- 5 Department of Cancer Control and Provention, Branch of Noncommunicable Disease and Injury, Shanghai Center for Disease Control and Prevention, Shanghai, China
- 6 Graduate School of Science and Engineering, Iryo Sosei University, Iwaki, Fukushima, Japan
- 7 Research Institute of Innovative Medicine, Tokiwa Foundation, Iwaki, Fukushima, Japan
- 8 Jing'an Preventive Medicine Association (the Jing'an Centre of Management & Service for Elderly Health), Shanghai, China

§Corresponding author:

Shigeaki Kato, PhD
Graduate School of Science and Engineering,
Iryo Sosei University,
5-5-1, Iino, Chuo-dai, Iwaki, Fukushima, 970-8551, Japan
shigeaki.kato@isu.ac.jp

Tel: +81-(0)246-29-5394, Fax: +81-(0)246-29-5414

Research Institute of Innovative Medicine, Tokiwa Foundation

32 57 Kaminodai, Jyoban Kamiyunagayamachi, Iwaki, Fukushima, 972-8322, Japan

33 TEL: +81-245-43-4175, FAX: +81-246-42-3153

34 E-mail: uskato0525@gmail.com

35

36 Xiaocang Ding, MSHA

37 Jing'an Preventive Medicine Association (the Jing'an Centre of Management & Service for Elderly
38 Health), Shanghai, China

39 Room 2105, No. 433 Jiaozhou Rd. Shanghai, 200040, China

40 TEL: +86-021-62361512, FAX: +86-021-62361512,

41 E-mail: xcding126@126.com

42

43

44 **Short title:** Low rate of follow-up colonoscopy in a Chinese urban core district

45 **Word count:** 4883 words

46 **Competing Interests:** The authors have declared that no competing interests exist.

47

48

49

Abstract

Colorectal cancer (CRC) is one of the most common cancers in China. In 2003, a systematic CRC registry that enables the determination of CRC incidence and mortality and a CRC screening project were introduced in the Jing'an district of Shanghai by the municipal government. This study assessed the registry data to determine the status of CRC and CRC screening rates in the core district of an urban area of China. Data were retrieved from the Official registry information systems of Jing'an district Shanghai Cance. The incidence and mortality of CRC, as well as population-based CRC screening rates, were analysed. Individuals who screened positive for CRC based upon results of a high-risk factor questionnaire (HRFQ) and a faecal immunochemical test (FIT) were selected for follow-up colonoscopy (CSPY). From the registry data collected between 2003 and 2013, the standardized incidence rate was 26.44/10⁵, with a significant gender difference. The CRC standardized mortality rate was 10.08/10⁵. In 2013, 17,866 individuals (21.6%) enrolled for CRC screening among the 82,602 candidate residents. The positive screening rate was 16.28% (2909/17866). Among the 2909 positives, 508 (17.5%) underwent follow-up CSPY. In 41.3% of these individuals (210/508), abnormal lesions were detected. Of these, 8 (1.57%) lesions were diagnosed as CRC, and 142 (28.0%) were identified as precancerous lesions. During the assessment period, both the incidence and mortality of CRC in the Jing'an district were determined in the area of high CRC prevalence in Chin. Nevertheless, the rate of participation in CRC screening was low (21.6%), and the rate of participation in follow-up CSPY for individuals who screened positive was only 17.5%. Improved participation in CRC screening and follow-up CSPY is expected to lower the incidence and mortality of CRC significantly in the rural areas of China. (288)

81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110

Introduction

Colorectal cancer (CRC) is one of the most commonly diagnosed cancers in males and in females worldwide.[1-3] CRC has a high prevalence, and it has become widely viewed as having a long latency period, providing ample time for both early detection and prevention. Indeed, if diagnosed at the earliest stage, CRC can be treated successfully, and most patients will survive for more than five years.

Research has shown that CRC screening reduces the incidence and mortality of CRC. A meta-analysis of trials demonstrated that CRC mortality could be reduced by 16% for those invited to screening.[4] Based on the effectiveness of screening, a guideline for screening and surveillance for the early detection of CRC and adenomatous polyps was published jointly by the American Cancer Society, the US Multi-society Task Force on CRC, and the American College of Radiology in 2008.[5] Similar systems and guidelines for CRC screening have been established in other Western and Asian countries as well.[6-12] In China, several large-scale population screenings using the Sequential Fecal Occult Blood Screening Program were performed by the municipals, and the public data reported in the several Chinese medical journals showed high rates of CRC and adenomatous polyps that were similar to those reported in other countries.[13-16] Furthermore, to facilitate CRC screening, a high-risk factor questionnaire (HRFQ) was generated and applied for the CRC screening from 1992. However, as there is huge diversity in the urban as well as the rural areas in China, mainly derived from the availability of medical resources and mobility of the residents, little information was available for accurate assessment of the CRC incidence and mortality of permanent residents.

In the urban areas of Shanghai, CRC was ranked higher in incidence (second) and mortality (fourth) among all malignant tumours from the public data source released from the municipals. The Jing'an district is small (0.12% of the total Shanghai area), but it is located in the core and most fruitful centre of Shanghai in terms of economical and medical resources, with a higher life expectancy than the entire Shanghai area in 2015. Owing to this situation, the residents of this district tend to live there permanently. Therefore, this district appears appropriate for assessment of CRC incidence and

mortality, as well as the rate of participation in CRC screening, as a representative urban area in China.

To accurately assess CRC incidence and mortality and the rate of participation in CRC screening in urban areas, the present study was conducted by retrieving the related informations of the residents of the Jing'an district from the Registry Information Systems in Shanghai for analyses. The results showed a high CRC incidence and mortality during the assessment period, together with a low participation rate in CRC screening (21.6%). Notably, only 17.5% (508) of the 2,909 individuals who screened positive for CRC were found to take follow-up colonoscopy (CSPY) in 2013.

Materials and methods

Data source for CRC incidence and mortality assessment

In Shanghai, cause of death monitoring began in the 1950s. The Shanghai All Causes of Death Registration Reporting System was established in every district of Shanghai in 1973. The Cancer Prevention and Control Office was established in 1986. In 2001, the Shanghai Municipal Health and Family Planning Commission launched the Shanghai Malignant Tumor Report Methods. Since then, hospital tumour registration and reporting has been standardized, and the Shanghai Cancer Registry Information System has been used. We retrieved the related informations from the Jing'an district CDC (Shanghai Jingan Center for Disease Control and Prevention), through the Shanghai Cancer Registry Information System and the Shanghai All Causes of Death Registration Reporting System organized by the Shanghai Government and Jingan municipal office.

The CRC screening was conducted by six sites of the community health service center in this district under supervise by the health bureau of the Shanghai Government and Jingan municipal office. Colonoscopy and the follow-up diagnosis for further treatment under supervise by the health bureau were performed in the four designated hospitals (Jing'an District Central hospital, Huashan hospital, Huadong hospital and Post & Telecommunications Hospital of Shanghai.).

Incidence and mortality rate and standardization

Data for the registered population was obtained from the Jing'an District Public Security Bureau to calculate the crude incidence (mortality) rate. We used the 1966 world standard population composition [17] to calculate the world population-adjusted incidence (mortality), which was referred to as the standardized rate.

Data source for screening

The Shanghai CRC Screening Information System has been used since 2013, when population-based CRC screening was introduced in Shanghai. We obtained the data from the Shanghai CRC Screening Information System of the Jing'an district. The project population consisted of the resident population from 50 to 74 years of age, and 82,602 persons were offered screening based on China's sixth census of the resident population in the Jing'an district.

Evaluation

Based on the Shanghai Community Residents CRC Screening Program, we adopted a two-step protocol for population-based CRC screening: (1) an initial high-risk factor questionnaire (HRFQ) and faecal immunochemical test (FIT) followed by (2) a full CSPY for those cases identified as positive in the initial screening. When participants with either a positive HRFQ or one of two FITs proved positive, they were referred for CSPY.

HRFQ

According to the "CRC Risk Assessment Form for Shanghai Community Residents", we evaluated the CRC risk of the target population and screened out high-risk groups by: (1) first-degree relative(s) with CRC; (2) personal history of cancer; (3) personal history of intestinal polyps; (4) two or more of the following symptoms/histories: (4a) chronic diarrhoea (diarrhoea lasting for more than 3 months in the last two years, and each episode lasting for more than 1 week); (4b) chronic constipation (over the past two years, constipation lasting for more than two months every year); (4c) mucous and bloody stool; (4d) major trauma or painful event (e.g. divorce, death of relatives); (4e) history of chronic appendicitis or appendectomy; (4f) history of chronic cholecystitis or cholecystectomy. If an individual was positive for any one of the 4 items above, the result was

considered positive on the HRFQ.

Examinations

The FIT was performed 2 times per person at a one-week interval. Participants were informed of the significance of the positive results and given a referral for CSPY to be carried out at a designated hospital. These designated hospitals were asked to input CSPY information in a timely manner.

Quality control

A random sample of 2% each day was checked, and the coincidence rate was not less than 90%. After the original questionnaire information was entered, the coincidence rate of the information system and the questionnaire should be 100%.

Statistical analyses

Categorical data were analysed using the Chi-square test, and a difference of $P < 0.05$ was considered statistically significant. Using SAS 9.1.3, we compared detection rates with Fisher's Exact Test (two-sided) on both sides of the Exact P -value, recording the P -value of the Chi-square at the same time. Chi-square was analysed by age group, using hierarchical analysis.

Results

Incidence and mortality of CRC in the Jing'an district from 2003 to 2013

The crude and standardized incidence rates of CRC between 2003 and 2013 were 66.18/10⁵ and 26.44/10⁵ (Table 1).

Table 1 CRC incidence rate by year and sex (2003-2013) (/100 thousand)

	male						female						total	
	Colon cancer		Rectal cancer		total		Colon cancer		Rectal cancer		total			
	crude	standard	crude	standard	crude	standard	crude	standard	crude	standard	crude	standard	crude	standard
2003	32.35	14.42	21.15	10.45	53.51	24.88	35.58	13.49	15.68	7.28	51.26	20.77	52.37	23.04
2004	39.01	19.27	30.05	12.59	69.06	31.86	36.39	13.23	21.59	9.40	57.97	22.63	63.42	26.82
2005	37.80	17.47	26.72	14.47	64.52	31.94	44.45	15.74	24.42	9.71	68.87	25.45	66.73	28.80
2006	37.62	17.12	27.06	12.77	64.68	30.54	44.22	14.93	25.27	10.24	69.49	25.17	67.14	27.84
2007	42.33	16.47	25.80	11.90	68.13	28.37	46.67	18.74	20.18	7.10	66.85	25.84	67.47	26.80
2008	43.29	19.31	26.64	12.00	69.93	31.31	35.20	12.06	18.23	7.71	53.44	19.77	61.45	25.25
2009	37.96	13.62	25.31	9.82	63.27	23.44	41.49	14.79	20.75	8.14	62.24	22.93	62.74	23.09
2010	38.35	14.60	26.91	10.79	65.26	25.39	41.12	12.99	19.61	5.75	60.73	18.75	62.92	21.92
2011	43.55	15.90	29.26	12.32	72.81	28.22	52.33	19.49	26.80	9.51	79.13	29.00	76.07	28.50
2012	63.06	24.53	32.90	13.03	95.96	37.56	34.68	11.17	28.25	11.04	62.93	22.22	78.91	29.44
2013	42.26	17.71	33.25	13.21	75.51	30.92	47.33	16.84	18.16	10.44	65.49	27.28	70.34	29.08
2003-2013	41.44	17.45	27.65	12.14	69.09	29.59	41.72	14.83	21.69	8.81	63.41	23.63	66.18	26.44

The age of onset of colon cancer ranged from 17 to 97 years, and the age of onset of rectal cancer ranged from 13 to 99 years; the median values were 74 and 71 years, respectively. The incidence of colon cancer and rectal cancer increased with age, and showed a rapid rise after about 50 years of age; the peak was in the range of 75-80 years of age (Fig.1 CRC incidence rate by age in males and females (2003-2013) (/100 thousand)). Statistically significant gender differences in CRC incidence were found ($P=0.0431$). The standardized incidence rate of colon cancer in males and females was 17.45/10⁵ and 14.83/10⁵, respectively, and that of rectal cancer in males and females was 12.14/10⁵ and 8.81/10⁵, respectively (Table 1 and Fig. 2 Standardized incidence rate by sex (2003-2013) (/100 thousand)). Pathological diagnosis accounted for 73.57% of the CRC incidence (Table 2).

217 Table 2 **Diagnostic characteristics of highest CRC incidence (2003-2013)**

	male						female						total	
	Colon cancer		Rectal cancer		total		Colon cancer		Rectal cancer		total			
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Pathology (primary)	518	75.00	340	74.07	858	74.63	518	70.78	287	75.73	803	72.47	1659	73.57
Clinical	52	7.56	59	12.85	111	9.68	82	11.25	43	11.35	125	11.28	236	10.47
X-ray, ultrasound, endoscope, CT	80	8.72	38	8.28	98	8.54	75	10.29	28	7.39	103	9.30	201	8.91
Biochemistry and immunity	25	3.63	5	1.09	30	2.62	28	3.57	10	2.64	38	3.25	66	2.93
Operation and autopsy	18	2.33	9	1.96	25	2.18	12	1.65	6	1.58	18	1.62	43	1.91
Pathology (secondary)	14	2.03	4	0.87	18	1.57	15	2.06	2	0.53	17	1.53	35	1.55
Blood smear and cytology	2	0.29	3	0.65	5	0.44	1	0.14	1	0.26	2	0.18	7	0.31
Registration of death	3	0.44	1	0.22	4	0.35	2	0.27	2	0.53	4	0.36	8	0.35
	688	100	459	100	1147	100	729	100	379	100	1108	100	2255	100

218
219 The crude and standardized CRC mortality rates were 33.10/10⁵ and 10.08/10⁵ (Table 3).

220
221 Table 3 **CRC mortality rate by year and sex (2003-2013) (/100 thousand)**

	male						female						total	
	Colon cancer		Rectal cancer		total		Colon cancer		Rectal cancer		total			
	crude	standard	crude	standard	crude	standard	crude	standard	crude	standard	crude	standard	crude	standard
2003	19.91	10.15	9.95	3.55	29.86	13.71	18.09	7.31	8.44	1.64	26.53	8.95	28.17	11.00
2004	24.94	12.26	7.67	2.34	32.61	14.60	17.89	4.73	11.10	2.21	28.99	6.94	30.77	10.75
2005	24.11	10.40	12.38	3.07	36.49	13.47	18.78	5.92	8.14	1.46	26.92	7.38	31.61	10.19
2006	23.76	10.57	11.22	2.97	34.98	13.54	24.64	10.01	11.37	1.95	36.01	11.96	35.50	12.60
2007	27.78	9.85	13.23	3.37	41.01	13.23	18.92	6.74	8.83	1.50	27.75	8.24	34.22	10.32
2008	17.90	8.81	12.59	3.14	30.49	11.95	13.20	5.77	13.83	2.11	27.03	7.88	28.71	10.16
2009	28.26	11.16	16.82	3.95	45.07	15.11	18.34	6.61	14.55	2.19	32.89	8.80	38.48	11.61
2010	11.57	5.24	13.61	3.11	25.18	8.35	20.42	7.79	12.12	1.69	32.54	9.48	28.69	8.81
2011	28.79	10.88	12.34	2.53	41.13	13.41	17.98	6.83	17.34	2.35	35.32	9.17	37.87	11.21
2012	20.78	8.30	18.70	3.83	39.49	12.13	16.86	6.17	16.86	2.27	33.72	8.44	36.14	10.13
2013	21.09	7.57	14.76	2.83	35.85	10.40	18.38	6.44	15.75	2.00	34.13	8.44	34.50	9.30
2003-2013	22.53	9.53	12.95	2.61	35.48	12.15	18.43	6.77	12.42	1.58	30.84	8.35	33.10	10.08

222
223 The age of death due to colon cancer ranged from 53 to 80 years of age, and the age of death due to
224 rectal cancer ranged from 80 to 100 years of age. The median age of death due to colon and rectal
225 cancers was 73 and 85 years, respectively. Colon cancer mortality increased at about 50 years of age,
226 with peak mortality at about 75 years of age, and then it decreased, exhibiting an “inverted V” shape.
227 Rectal cancer mortality rose rapidly from about 75 years of age, increasing with age (Fig. 3 CRC
228 mortality rate by age in males and females (2003-2013) (/100 thousand)). There were also
229 statistically significant gender differences in CRC mortality ($P=0.0201$). The standardized mortality
230 rate of colon cancer in males and females was 9.53/10⁵ and 6.77/10⁵, respectively, and that for rectal

cancer in males and females was 2.61/10⁵ and 1.58/10⁵, respectively (Table 3 and Fig. 4 Standardized mortality rate by sex (2003-2013) (/100 thousand)). Pathological diagnosis accounted for 62.0% of the CRC mortality (Table 4).

Table 4 Diagnostic characteristics of highest CRC mortality (2003-2013)

	male						female						total	
	Colon cancer		Rectal cancer		total		Colon cancer		Rectal cancer		total			
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Pathology	222.0	59.4	149.0	86.8	365.0	62.1	191.0	59.3	149.0	65.8	334.0	61.9	699.0	62.0
Physical and chemical examination	148.0	39.8	69.0	32.2	217.0	36.9	126.0	39.1	69.0	31.7	195.0	36.1	412.0	36.5
Operation	4.0	1.1	2.0	0.9	6.0	1.0	3.0	0.9	5.0	2.3	8.0	1.5	14.0	1.2
Clinical	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.5	1.0	0.2	1.0	0.1
Chemical examination	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.3	0.0	0.0	1.0	0.2	1.0	0.1
Autopsy	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.3	0.0	0.0	1.0	0.2	1.0	0.1
	374	100	214	100	588	100	322	100	218	100	540	100	1128	100

Rates of participation in CRC screening in the Jing'an district in 2013

In 2013, for the 82,602 eligible residents, a total of 17,866 underwent CRC screening (21.6%). The compositions of age, sex, marriage and education of the participants are shown in Table 5.

Table 5 Characteristics of the 17866 participants

	n	(%)
Age		
50-59	7670	42.93
60-69	8367	46.83
70-74	1829	10.24
	17866	100
Sex		
male	7052	39.47
female	10814	60.53
	17866	100
Marital status		
married	16175	90.54
widowed	658	3.68
divorced	434	2.43
single	474	2.65
unknown	125	0.7
	17866	100
Education		
none	66	0.37
primary school	685	3.83
technical secondary school/middle school	12802	71.66
undergraduate/postsecondary	4211	23.57
graduate	102	0.57
	17866	100

The total positive rate by either the HRFQ and/or the FIT was 16.28% (2909/17,866). The HRFQ positive rate was 7.49% (1339/17,866), while the FIT positive rate was 9.9% (1761/17,866) (Table 6).

Table 6 Positive screening questionnaire and FIT

HRFQ													X ² _{MH}	P	
50-59				60-69			70-74			total					
		-	+			-	+			-	+				
FIT		-	0	1148	1148	0	0	0	26	0	26	0			1148
	+	730	191	921	799	0	799	41	0	41	1570	191	1761		
		730	1339	2069	799	0	799	41	0	41	1570	1339	2909	1405.3195	<0.0001

The compositions of age, sex, marriage and education of those who screened positive are shown in Table 7.

Table 7 Characteristics of the 2909 subjects who screened positive

	group	n	(%)
Age			
	50-59	2069	71.1
	60-69	799	27.5
	70-74	41	1.4
Sex			
	male	966	33.2
	female	1943	66.8
Marital status			
	married	2591	89.1
	divorced	81	2.8
	widowed	148	5.1
	single	71	2.4
	unknown	18	0.6
Education			
	none	10	0.3
	primary school	101	3.5
	technical secondary school/middle school	2022	69.5
	undergraduate/postsecondary	760	26.1
	graduate	16	0.6

Low rates of participation in follow-up colonoscopy in the Jing'an district in 2013

The 2909 individuals who screened positive for CRC were referred to four designated hospitals for follow-up colonoscopy (CSPY). However, only 508 (17.5%) underwent CSPY in 2013 (Fig. 5 Flow-chart of the screening program). The outcome of CSPY was normal for 282 (55.5%), abnormal for 210 (41.3%), and unknown for 16 (3.1%). Eight cases were diagnosed as CRC (1.6%), and 142 cases were diagnosed as precancerous lesions (28.0%) (Table 8).

Table 8 Clinical characteristics of the 508 colonoscopy cases

	male												female											
	50-54		55-59		60-64		65-69		70-73		total		50-54		55-59		60-64		65-69		70-73		total	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Normal	7	3.4	13	6.4	32	15.6	24	11.7	18	8.8	94	45.9	29	9.5	58	19.2	64	21.2	23	7.6	14	4.7	188	
Abnormal																								
CRC	0	0.0	1	0.5	0	0.0	1	0.5	2	1.0	4	2.0	0	0.0	0	0.0	2	0.7	0	0.0	2	0.7	4	
Precancerous lesion																								
tubular adenoma	3	1.5	2	1.0	16	7.8	10	4.9	4	2.0	35	17.1	2	0.7	5	1.7	6	2.0	11	3.6	9	3.0	33	
villous adenoma	5	2.4	4	2.0	13	6.3	14	6.8	7	3.4	43	21.0	4	1.3	6	2.0	5	1.7	10	3.3	5	1.7	30	
other lesions adenoma with moderate and severe dysplasia	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	
Others																								
enteritis	0	0.0	1	0.5	0	0.0	0	0.0	2	1.0	3	1.5	2	0.7	5	1.7	3	1.0	0	0.0	1	0.3	11	
inflammatory polyp	0	0.0	2	1.0	2	1.0	2	1.0	1	0.5	7	3.4	0	0.0	6	2.0	1	0.3	1	0.3	2	0.7	10	
hyperplastic polyp	0	0.0	1	0.5	4	2.0	4	2.0	2	1.0	11	5.4	3	1.0	2	0.7	3	1.0	4	1.3	2	0.7	14	
others	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	1	0.5	1	0.3	0	0.0	0	0.0	2	0.7	0	0.0	3	
Unknown	0	0.0	2	1.0	1	0.5	1	0.5	2	1.0	6	2.9	1	0.3	3	1.0	1	0.3	2	0.7	3	1.0	10	
Total	15	7.3	27	13.2	68	33.2	56	27.3	39	19.0	205	100	42	13.9	85	28.1	85	28.1	53	17.5	38	12.5	303	

The diagnostic stages of CRC are shown in Table 9.

Table 9 TNM classification of the 8 CRC cases

n	T	N	M
1	T ₁	N ₀	M ₀
2	T ₃	N ₀	M ₀
2	T _{4a}	N ₀	M ₀
1	T _{4a}	N ₁	M ₀
2	Unknown		

Discussion

CRC incidence and mortality in the Jing'an district were similar to those of the entire Shanghai area, which is among the areas of high CRC incidence and mortality in China

The standardized CRC incidence and mortality rates assessed between 2003 and 2013 were 26.44/10⁵ and 10.08/10⁵, respectively in the Jing'an district, similar to those between 2003 and 2007 (22.23/10⁵ and 12.96/10⁵) and (20.19/10⁵ and 9.22/10⁵) in the entire Shanghai area calculated by the municipals. From other surveys of the data calculated by the municipals in other cities and counties of China between 1998 and 2002, the CRC standardized incidence rates in Shanghai males and females were 20.4/10⁵ for males and 25.5/10⁵ for females, and the CRC standardized mortality rates

were $15.1/10^5$ for males and $11.6/10^5$ for females. These rates of CRC incidence and mortality in Shanghai were higher than those in the other core cities in China. Combined with the results of the present study, it is evident that Shanghai is a city of high CRC incidence and mortality among Chinese core cities, and the Jing'an district appears to be representative of an urban district of Shanghai. Even though the rates of CRC incidence and mortality in the Jing'an district were relatively high compared with other Chinese areas, they are still lower than those in the Western countries.[1-3] In the US, the CRC incidence rate in 2010 was estimated at $40/10^5$, and the CRC mortality rate was estimated at $15/10^5$. [18] However, in China, other data have suggested gradual increases in CRC incidence and mortality, presumably owing to a shift to a more Western lifestyle with regard to food, physical activity, etc. These tendencies in age-related increases and gender differences in CRC incidence and mortality in the Jing'an district [Table 1-2, Fig. 1-4] were consistent with those in past reports in other areas in China and other countries.[1,19] The gender difference in China might be due, in part, to a greater awareness of prevention in females than in males.

Combined use of FIT and HRFQ was effective in CRC screening programs as an initial screening method

For CRC screening, we utilized the Consensus in Early Diagnosis and Early Treatment, Comprehensive Prevention of China CRC Screening approach, using HRFQ, and FIT was used instead of guaiac fecal occult blood test (gFOBT).[20,21]. The FIT test was an immunoassay to detect faecal human haemoglobin at very low concentrations, and was considered more sensitive than the gFOBT.[22] Moreover, FIT is advantageous in providing a quantitative result that enables users to set acceptable rates of screening positives.[23] Though further improvement in the FIT assessment and development of other assessments are in progress[24-29], the FIT used in this study appears reliable and appropriate for CRC screening at this stage.

Follow-up colonoscopy (CSPY) is indispensable for reducing CRC mortality in individuals who screen positive for CRC

CSPY is considered the gold standard for the diagnosis of CRC and polyps to prevent death, and it is the most effective strategy to identify polyps at the initial stages. Moreover, CSPY is a less invasive

method to remove colorectal adenomas immediately upon identification. Thus, it is evident that CSPY surveillance is beneficial for most patients with intermediate-risk adenomas.[30] At present, other screening methods include ultrasound endoscopy (EUS), positron-emission tomography (PET) and genetic diagnosis.[31]. More recently, colon capsule endoscopy (CCE) was proposed for CRC screening by the European Digestive Disease Week and the World Congress of Gastrointestinal Disease.[32]. However, with CCE, it is impossible to obtain histological samples, and it is more expensive, although it is much more acceptable than CSPY in terms of pain expectations.[33]. In this study, among the 508 patients who underwent follow-up CSPY, 210 (41.3%) were judged as abnormal, and 8 (3.1%) were diagnosed with CRC (Table 7). Given that previous data indicated that only 62.0% of CRC deaths had a pathological diagnosis, follow-up CSPY is quite effective for the prevention of CRC mortality.

Low participation rate in follow-up CSPY after CRC screening

Regardless of the significance of follow-up CSPY to reduce CRC mortality, the rate of participation in follow-up CSPY after CRC screening in 2013 was only 17.5% (508/2909) in this study. From the registry of the Shanghai CRC Screening Information System, the rates of participation in follow-up CSPY from 2014 to 2016 in the Jing'an district were also only 11.65% (72/618) in 2014 and 5.43% (59/1086) in 2015. Such annual decreases in the rates of participation were also recorded for the initial CRC screening [18.28% (618/3380) in 2014 and 26.92% (1086/4034) in 2015]. Moreover, a similarly low rate of follow-up CSPY participation was found between 2012 and 2013, as only 9.51% (1000/10512) was reported in the Xuhui District.[34] These low rates of follow-up CSPY screening after positive results of CRC screening in China, at least in the urban areas, are striking, since much better rates of participation in follow-up CSPY have been reported in the US (more than 50%) [35] and Japan (69.1% = 10593/153320 positives, among 2535814 participants in CRC screening in 2016).[36]

Similarly, in a study of the national screening programme in England, about 60% of the individuals who screened positive for CRC participated in follow-up CSPY screening in two years later.[37] The exact reason for such a low rate of participation in follow-up CSPY in China remains to be studied, but several issues could be responsible. CSPY requires several steps, such as bowel preparation and a

complex procedure with possible complications, which may deter individuals who screen positive for CRC from undergoing CSPY. It is also suggested that even if the initial CRC test is abnormal, some individuals may feel that further follow-up with CSPY screening is unnecessary.

CRC and follow-up CSPY screenings are effective in reducing CRC incidence and preventing CRC mortality

Decreasing CRC mortality rates have been observed in a large number of countries worldwide. This trend is assumed to be attributed mainly to CRC screening. [38,39]. For example, CRC mortality rates declined by 47% among men and by 44% among women from 1990 to 2015 in the United States, and in 1995, the US Preventive Services Task Force (USPSTF) endorsed screening with faecal occult blood testing (FOBT) and flexible sigmoidoscopy. New guidelines released by the USPSTF in 2016 emphasized the benefits of CRC screening in average-risk individuals, and listed 8 possible screening programs that could reduce CRC mortality.[40] In Germany, within 10 years of the introduction of screening CSPY, the incidence of bowel cancer in persons over the age of 55 fell by 17–26%, after having risen steadily over the preceding decades.[41] The UK bowel cancer awareness campaigns appeared to have improved public awareness of CRC and encouraged symptomatic individuals to seek urgent medical attention.[42] In Australia, Australian National Bowel Cancer Screening Program (NBCSP) invitees had less risk of dying from CRC[43], and were more likely to have less-advanced disease when diagnosed compared with noninvitees, and the potential benefits of a program similar to the NBCSP may become available to an increasing number of countries.

The present study indicate that efforts are required for rigorous improvement in CRC and follow-up screenings in China. Regarding the low rates of CRC screening, some factors affecting participation like socio-demographic characteristics (educational level, health insurance, and knowledge of CRC and CRC screening), psychological factors (perceived severity of CRC, susceptibility to CRC, and barriers to screening), and contact with medical provider (physician recommendation) could be considered.[44] To improve participation in CRC screening in China, more studies are clearly needed to address these points including a longer follow-up of the present study, to better inform the citizens regarding the benefits of CRC screening.

Conclusion

The incidence and mortality of CRC were high in the Jingan district, a representative urban Chinese area. Nevertheless, the rates of participation in CRC screening and in follow-up CSPY for individuals who screened positive were quite low when compared to those reported in other countries. Therefore, improvement in participation in CRC screening is important to significantly lower the incidence and mortality of CRC.

Acknowledgments

This study was funded by the Jingan District Shanghai Health and Family Planning Commission Programs, number JWXK201209. The study also received financial support from the Jingan District Government, and from Tokiwa Foundation for SK. We would like to thank all of the related staff in the Fudan University School of Public Health, Shanghai, China. We also thank the members of Medical Governance Research Institute, Tokyo, Japan and Ms. Rongrong Liang for supports, as well as personal assists.

References

1. Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel, et al. global cancer statistics,2012. CA A Cancer Journal for Clinicians, 2015, 65(2):87-108
2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015, 136(5):E359-386
3. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008[J]. Eur J Cancer, 2010, 46(4):765-781
4. Hewitson P, Glasziou PP, Irwig L, et al. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database of Systematic Reviews, 2007,24(1): CD001216. Doi:10.1002/14651858.CD001216.pub2
5. Levin B, Lieberman DA, McFarland B, et al; Screening and surveillance for the early detection

of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *CA Cancer J Clin*, 2008, 58(3):130-160

6. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer [J]. *Lancet*, 1996, 348(9040):1472-1477
7. Jack S. Mandel, Timothy R. Church, Fred Ederer, et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood [J]. *Journal of the National Cancer Institute*, 1999, 91(5):434-437
8. Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing : results after 13 years and seven biennial screening rounds [J]. *Gut*, 2002, 50(1):29-32
9. Zaval M, Suchanek S, Zavada F, et al. Colorectal cancer screening in Europe. *World J Gastroenterol*. 2009; 15(47): 5907-5915
10. Sung JJY, Lau JYW, Young GP, et al. Asia Pacific consensus recommendations for colorectal cancer screening. *Gut*, 2008, 57(8):1166-1176
11. Yeoh KG, Ho KY, Chiu HM, et al. Asia-Pacific Working Group on Colorectal Cancer. The Asia-Pacific Colorectal Screening score: a validated tool that stratifies risk for colorectal advanced neoplasia in asymptomatic Asian subjects. *Gut*, 2011, 60 (9):1236-1241
12. Halloran SP, Launoy G, Zappa M, European guidelines for quality assurance in colorectal cancer screening and diagnosis. first edition faecal occult blood testing. *Endoscopy*, 2012, 44 (3): 65-87
13. Wu Z, Wang Z, Li S. Discussion on sequential fecal occult blood test screening of colorectal cancer value. *Journal of Practical Oncology*, 1995, 10(4):223-224
14. Li S, Tian S, Wu Z, et al. Application of sequential fecal occult blood test in natural populations for screening of colorectal carcinoma. *World Journal of Gastroenterology*, 2004, 12(1): 137-139
15. Shaikat A, Mongin SJ, Geisser MS, et al. Long-Term Mortality after Screening for Colorectal Cancer. *N Engl J Med*. 2013. 369(12):1106-1114
16. Atkin WS, Edwards R, Kralj-Hans, et al. once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. *Lancet*. 2010, 375(9726):1624-1633

- 434 17. Doll R, Payne P, Waterhouse J. (eds). Cancer Incidence in Five Continents: A Technical Report.
435 1966, Berlin, Springer-Verlag (for UICC)
- 436 18. Rebecca L. Siegel, Kimberly D. Miller, Stacey A. Fedewa, et al. Colorectal Cancer Statistics,
437 2017. CA CANCER J CLIN, 2017,67 (3) :177-193
- 438 19. Regula J, Rupinski M, Kraszewska E, et al. Colonoscopy incolorectal-cancer screening for
439 detection of advanced neoplasia[J]. N Engl J Med, 2006, 355(18):1863-1872
- 440 20. Digestive Disease Branch of Chinese Medical Association. Consensus opinion on screening,
441 early diagnosis and early diagnosis of colorectal cancer in China (one). Chin J Gastroenterol [J],
442 2011.16 (11):666-675
- 443 21. Digestive Disease Branch of Chinese Medical Association. Consensus opinion on screening,
444 early diagnosis and early diagnosis of colorectal cancer in China (two). Chin J Gastroenterol [J],
445 2011.16 (12):735-744
- 446 22. Wise J. New bowel cancer screening test is recommended for England. BMJ. 2016; 352:i273
447 doi: 10.1136/bmj.i273 (Published 18 January 2016)
- 448 23. Moss S, Mathews C, Day TJ, et al. Increased uptake and improved outcomes of bowel cancer
449 screening with a faecal immunochemical test: results from a pilot study within the national
450 screening programme in England. Gut. 2016;0:1–14. doi:10.1136/gutjnl-2015-310691
- 451 24. Huang Y, Cai S, Zhang SC, et al. Preliminary study on the application value of screening
452 program for colorectal cancer in China [J]. Chinese Journal of preventive medicine, 2011,45 (7):
453 601-604
- 454 25. European Colorectal Cancer Screening Guidelines Working Group. European guidelines for
455 quality assurance in colorectal cancer screening and diagnosis : Overview and introduction to
456 the full Supplement publication. Endoscopy[J]. 2013, 45(1):51-59
- 457 26. Heitman S J, Hilsden R J, Au F, et al. Colorectal cancer screening for average-risk
458 NorthAmericans : an economic evaluation[J]. PLoS Med, 2010, 7(11)e1000370
459 doi:10.1371/journal.pmed.1000370
- 460 27. Sung JJ, Ng SC, Chan FK, et al. An updated Asia Pacific Consensus Recommendations
461 on colorectal cancer screening. Gut. 2015, 64(1):121-32. doi: 10.1136/gutjnl-2013-306503.
462 Epub 2014 Mar 19
- 463 28. Huang W, Liu G, Zhang X, et al. Cost-effectiveness of colorectal cancer screening protocols in

- 464 urban Chinese. Plos one. 2014, 9(10):1-8
- 465 29. Duffy MJ, Rossum LG, van Turenhout ST, et al. Use of faecal markers in screening for
466 colorectal neoplasia : a European group on tumor markers position paper[J]. Int J Cancer,
467 2011, 128(1):3-11
- 468 30. Atkin W, Wooldrage K, Brenner A, et al. Adenoma surveillance and colorectal cancer incidence:
469 a retrospective, multicentre, cohort study. Lancet Oncol. 2017, 18(4):823-834)
- 470 31. Plumb AA, Halligan S, Nickerson C, et al. Use of CT colonography in the English Bowel
471 Cancer Screening Programme. Gut. 2014, 63(6): 964-973
- 472 32. Zavoral M ,Suchanek S , Majek O, et al. Corectal cancer screening: 20 years of development and
473 recent progress. World Journal of Gastroenterology. 2014, 20(14):3825-3834)
- 474 33. Inadomi JM, Solomon CG. Screening for colorectal neoplasia. N Engl J Med.
475 2017,376(2):149-156)
- 476 34. Xia P. Colorectal cancer screening for average-risk population in Xuhui district of Shanghai.
477 Master's degree thesis. 2015, Jiangsu University
- 478 35. Singal AG, Gupta S, Skinner CS, et al. Effect of colonoscopy outreach vs fecal immunochemical
479 test outreach on colorectal cancer screening completion a randomized trial. JAMA. 2017,
480 806-815
- 481 36. http://www.jcancer.jp/about_cancer_and_checkup/
- 482 37. Mayor S. More than a third of people with abnormal bowel cancer screening results avoid later
483 screening. BMJ, 2015; 350: h77 doi: 10.1136/bmj.h77 <http://www.bmj.com/permissions>
- 484 38. Welch HG, Robertson DJ. Colorectal Cancer on the Decline - Why Screening Can't Explain It
485 All. N.Engl. J.Med 2016, 374(17):1605-1607
- 486 39. Navarro M, Nicolas A, Ferrandez A, et al. Colorectal cancer population screening programs
487 worldwide in 2016: An update. World journal of gastroenterology. 2017, 23(20):3632-3642)
- 488 40. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. US Preventive Services Task Force.
489 Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement.
490 JAMA. 2016; 315(23):2564-2575)
- 491 41. Brenner H, Petra Schrotz-King, Bernd Holleczek, et al. Declining Bowel Cancer Incidence and
492 Mortality. Deutsches Ärzteblatt International ,2016; 113(7): 101–106
- 493 42. Khong TL, Naik K, Sivakumar R, et al. Impact of the United Kingdom national bowel cancer

awareness campaigns 2012 on colorectal cancerservices and patient survival. Colorectal Disease.
2015, 17(12):1055-1061

43. Ananda S, Wong SH, Faragher I, et al. Survival impact of the Australian National Bowel Cancer
Screening Programme. Internal Medicine Journal. 2016, 46(2):166-171

44. Leung DY, Chow KM, Lo SW. Contributing factors to colorectal cancer screening among
chinese people: a review of quantitative studies. International Journal of Environmental
Research and Public Health, 2016, 13(5):506-527

Fig. 1 CRC incidence rate by age in males and females (2003-2013) (/100 thousand)

Fig. 2 Standardized incidence rate by sex (2003-2013) (/100 thousand)

Fig. 3 CRC mortality rate by age in males and females (2003-2013) (/100 thousand)

Fig. 4 Standardized mortality rate by sex (2003-2013) (/100 thousand)

Fig. 5 Flow-chart of the screening program